Bond.az reports that Poolbeg Pharma plc (AIM:POLB) has received feedback from the U.S. Food and Drug Administration (FDA) regarding POLB 001, its therapy for Cytokine Release Syndrome in cancer immunotherapy.
The FDA provided input on the clinical development strategy, aligning with key aspects of the company's proposed pathway for POLB 001.
Alignment was reached on the primary endpoint for a future Phase 3 trial, providing clarity for ongoing partnership discussions.
POLB 001 is designed to prevent Cytokine Release Syndrome, a side effect of cancer immunotherapy.
Bruno Speder, VP of Regulatory Affairs, confirmed the FDA feedback and alignment on the development pathway.
The announcement does not imply FDA approval or endorsement of safety or efficacy. The meeting was solely for regulatory guidance.
Poolbeg Pharma is a clinical-stage biopharmaceutical company focused on cancer immunotherapy and also developing an oral GLP-1 therapy for obesity.
